Patterns of index biologic drug registrations to a pharmacovigilance register of psoriasis patients.

K.J. Mason¹, I. Evans¹, K. McElhone¹, M. Lunt⁴, S. Hussain⁴, B. Kirby¹, A.D. Burden¹, N.J. Reynolds⁶ and C.E.M. Griffiths¹

1. Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom;
2. British Association of Dermatologists, London, United Kingdom;
3. Dermatology Group, St Vincent’s University Hospital, Dublin, Republic of Ireland;
4. Department of Dermatology, Western Infirmary, Glasgow, United Kingdom;
5. Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom.

BACKGROUND

- The introduction of biologic therapies revolutionised treatment of psoriasis and psoriatic arthritis (PsA)
- Recommendations for treatment of psoriasis (Figure 1 and Table 1) and PsA (Table 2) with biologics revised over time.

RESULTS

- 6140 biologic naïve patients (82% biologic cohort); median age 45 years, inter-quartile range 36-54 years; 60% male.
- Registrations by country: England (n=4497; 76%); NI (n=299; 5%); ROI (n=289; 5%); Scotland (n=525; 9%); Wales (n=330; 5%).
- Humira (57%) was the most common index biologic (23% Enbrel; 18% Stelara; 2% Remicade).

CONCLUSION

- Registrations to BADBIR reflect index biologic prescribing practices in biologic-naïve psoriasis patients.
- Humira was the most commonly prescribed index biologic drug across the UK and ROI.
- First line Enbrel prescribing decreased and Stelara increased over time in the UK; however, Enbrel use was common in ROI, with few index registrations of Stelara.
- Future work will explore which baseline factors influence index biologic therapy prescribing practices.

REFERENCES


ACKNOWLEDGEMENTS

The authors express their gratitude to all patients, centres, the BADBIR team, BAD, sponsors, and all current and/or former members of the BADBIR steering committee.

Disclosures: BADBIR is coordinated by the University of Manchester. BADBIR is funded by the British Association of Dermatologists (BAD). The BAD receives income from AbbVie, Janssen Cilag, Novartis, Samsung Biopis and Pfizer for providing pharmacovigilance services. This income finances a separate contract between the BAD and the University of Manchester who coordinate BADBIR. All decisions concerning analysis, interpretation, and publication are made independently of any industrial contribution.

KJM received lecture fees from Janssen Cilag (Dec. 2015) and Eli Lilly (May 2016).